当前位置： SCI文献检索 > CLINICAL THERAPEUTICS期刊下所有文献 > Estrogen in cardiovascular disease during systemic lupus erythematosus.

Estrogen in cardiovascular disease during systemic lupus erythematosus.

Abstract：

PURPOSE:Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that disproportionately affects women during their childbearing years. Cardiovascular disease is the leading cause of mortality in this patient population at an age when women often have low cardiovascular risk. Hypertension is a major cardiovascular disease risk factor, and its prevalence is markedly increased in women with SLE. Estrogen has traditionally been implicated in SLE disease progression because of the prevalence of the disease in women; however, its role in cardiovascular risk factors such as hypertension is unclear. The objective of this review is to discuss evidence for the role of estrogen in both human and murine SLE with emphasis on the effect of estrogen on cardiovascular risk factors, including hypertension. METHODS:PubMed was used to search for articles with terms related to estradiol and SLE. The references of retrieved publications were also reviewed. FINDINGS:The potential permissive role of estrogen in SLE development is supported by studies from experimental animal models of lupus in which early removal of estrogen or its effects leads to attenuation of SLE disease parameters, including autoantibody production and renal injury. However, data about the role of estrogens in human SLE are much less clear, with most studies not reaching firm conclusions about positive or negative outcomes after hormonal manipulations involving estrogen during SLE (ie, oral contraceptives, hormone therapy). Significant gaps in knowledge remain about the effect of estrogen on cardiovascular risk factors during SLE. Studies in women with SLE were not designed to determine the effect of estrogen or hormone therapy on blood pressure even though hypertension is highly prevalent, and risk of premature ovarian failure could necessitate use of hormone therapy in women with SLE. Recent evidence from an experimental animal model of lupus found that estrogen may protect against cardiovascular risk factors in adulthood. In addition, increasing evidence suggests that estrogen may have distinct temporal effects on cardiovascular risk factors during SLE. IMPLICATIONS:Data from experimental models of lupus suggest that estrogens may have an important permissive role for developing SLE early in life. However, their role in adulthood remains unclear, particularly for the effect on cardiovascular disease and its risk factors. Additional work is needed to understand the effect of estrogens in human SLE, and preclinical studies in experimental models of SLE may contribute important mechanistic insight to further advance the field.

journal_name

Clin Ther

journal_title

Clinical therapeutics

authors

Gilbert EL,Ryan MJ

doi

10.1016/j.clinthera.2014.07.021

subject

Has Abstract

pub_date

2014-12-01 00:00:00

pages

1901-1912

issue

eissn

0149-2918

issn

1879-114X

pii

S0149-2918(14)00494-9

journal_volume

pub_type

杂志文章,评审

在线工具

Estrogen in cardiovascular disease during systemic lupus erythematosus.